Diabetes & cardiometabolic
SGLT2 inhibitors, GLP-1 agonists and the obesity–heart-failure axis.
- Trials
- 13
- Years
- 2015–2025
Sort
- 2025SUMMITObesity & HFpEFIn 731 patients with HFpEF and obesity, tirzepatide reduced cardiovascular death or worsening heart failure compared with placebo.HR 0.62Read →
- 2025SURPASS-CVOTGIP/GLP-1 RAIn 13,299 patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was non-inferior for major adverse cardiovascular events compared with dulaglutide (HR 0.92, 95.3% CI 0.83-1.01).HR 0.9295.3% CI 0.83-1.01Read →
- 2025SOULoral GLP-1 RAIn 9,650 patients with type 2 diabetes and ASCVD, CKD, or both, oral semaglutide reduced major adverse cardiovascular events compared with placebo (HR 0.86, 95% CI 0.77-0.96).HR 0.8695% CI 0.77-0.96Read →
- 2025SURMOUNT-5GIP/GLP-1 RAIn 751 adults with obesity but without type 2 diabetes, tirzepatide reduced body weight at 72 weeks more than semaglutide (-20.2% vs -13.7%).-20.2% vs -13.7%Read →
- 2024FLOW CoreGLP-1 RAIn 3,533 patients with type 2 diabetes and CKD, semaglutide reduced the composite of kidney failure, ≥50% eGFR decline or renal/CV death compared with placebo.HR 0.7695% CI 0.66-0.88Read →
- 2023SELECT CoreGLP-1 RAIn 17,604 patients with obesity and cardiovascular disease but without diabetes, semaglutide reduced major adverse cardiovascular events compared with placebo.HR 0.8Read →
- 2021STEP 1Semaglutide for obesityIn 1,961 adults with overweight or obesity without type 2 diabetes, subcutaneous semaglutide 2.4 mg weekly reduced body weight at 68 weeks compared with placebo.-14.9% vs -2.4%Read →
- 2020DAPA-CKD CoreSGLT2 inhibitorsIn 4,304 patients with CKD with or without diabetes, dapagliflozin reduced the composite of ≥50% eGFR decline, ESKD or renal/CV death compared with placebo.HR 0.6195% CI 0.51-0.72Read →
- 2019DECLARE-TIMI 58SGLT2 inhibitorsIn 17,160 patients with type 2 diabetes, dapagliflozin reduced cardiovascular death or heart-failure hospitalisation compared with placebo.HR 0.83Read →
- 2019CREDENCE CoreSGLT2 inhibitorsIn 4,401 patients with type 2 diabetes and albuminuric CKD on maximal RAS blockade, canagliflozin reduced the composite of ESKD, creatinine doubling or renal/CV death compared with placebo.HR 0.7095% CI 0.59-0.82Read →
- 2016LEADERGLP-1 RAIn 9,340 patients with type 2 diabetes at high cardiovascular risk, liraglutide reduced major adverse cardiovascular events compared with placebo.HR 0.87Read →
- 2016SUSTAIN-6CV outcome trialIn 3,297 patients with T2DM at high CV risk, subcutaneous semaglutide 0.5 or 1.0 mg weekly reduced CV death, non-fatal MI or non-fatal stroke versus placebo.HR 0.74Read →
- 2015EMPA-REG OUTCOME CoreSGLT2 inhibitorsIn 7,020 patients with type 2 diabetes and cardiovascular disease, empagliflozin reduced cardiovascular death compared with placebo.HR 0.86Read →